Price · last 3 months · daily close
HSIC price
Loading the price chart...
Daily closing prices via yfinance. Quotes are delayed. Past prices are not a guarantee of future results.
ValeriusBeta - Not investment advice
Research · S&P 500 · Health Care
The numbers, the scorecard and what analysts say, with the source for each. Information, not advice.
Price · last 3 months · daily close
Loading the price chart...
Daily closing prices via yfinance. Quotes are delayed. Past prices are not a guarantee of future results.
Value Scorecard · run 2026-10-18
Earnings & returns
Diluted EPS: $3.91 (2022), $3.16 (2023), $3.05 (2024), $3.27 (2025). It ended at or below 2022; the framework scores that as 2.
ROE (net income / common equity): 15.6% (2022), 11.4% (2023), 11.5% (2024), 12.3% (2025). Median 11.9%, lowest 11.4%; the framework scores a median 10-15% as 3.
ROIC of 8.2%: operating income of $653.00M divided by $7.99B of capital (total assets $11.21B minus current liabilities $3.23B), fiscal year to Dec 27, 2025, as filed in the 10-K (SEC EDGAR). The framework scores 5-10% as 2.
Net margin of 3.0%; the framework scores 0-5% as 2; gross margin 31.3%, operating margin 5.8%.
Balance sheet & cash
Debt-to-equity of 0.81; the framework scores 0.8-1.5 as 3 (total debt $3.81B, total cash $157.00M).
Free cash flow (operating cash flow minus capital expenditure): $474.00M (2022), $313.00M (2023), $661.00M (2024), $521.00M (2025). It ended above 2022 but did not rise in 2 of 3 years; the framework scores that as 3.
Retained earnings, as filed in the 10-Ks (SEC EDGAR): $3.68B (2022), $3.86B (2023), $3.77B (2024), $3.29B (2025). It ended at or below 2022; the framework scores that as 2.
Valuation models
IV = EPS x (8.5 + 2g) x (4.4 / Y) = $3.43 x (8.5 + 2 x 1.7) x (4.4 / 4.5) = $39.91. Current price $86.38; price is 116.4% above the model value.
FCF/share = $3.915, stage 1 growth = 3.4% for 5 years, terminal growth = 3%, discount rate = 10%. Stage 1 PV = $16.32, PV of terminal value = $42.28, DCF value = $58.60. Current price $86.38; price is 47.4% above the model value.
Graham value $39.91 (price is 116.4% above the model value); DCF value $58.60 (price is 47.4% above the model value).
P/B of 3.06; the framework scores 3.0-5.0 as 2.
Business quality
A moat (a brand, a network, switching costs, patents, scale, a licence) is not a number in the filings, so Valerius doesn’t score it. Below are the figures and the words moat analysis starts from, from the company’s own 10-K filings. The conclusion is yours.
Return on capital, each year
Above 15% in 1 of 10 years (2016-2025); lowest 7.8%, highest 17.2%.
Gross margin, each year
Between 27.8% and 31.7% over 10 years (a range of 3.9 points).
Competition, in the company’s own words · 10-K filed Feb 24, 2026
The latest 10-K has no section headed “Competition” that could be quoted. Open the filing to read how the company describes its markets.
Return on capital = operating income / (total assets − current liabilities), the ROIC row’s definition; 15% is the framework’s return threshold. Gross margin = gross profit / revenue. Both from each year’s 10-K via SEC EDGAR. Moat analysis commonly looks at whether returns and margins held up over many years. These figures don’t say whether the company has an advantage, what it is, or whether it will last.
Capital allocation, 2022-2025: dividends or buybacks paid in every year (pass); $1.97B paid out against $1.97B of free cash flow (fail: paid out more than free cash flow); total debt $1.50B to $3.44B, up 129.5%, 3.6x EBITDA (fail: up more than 10% and above 2x EBITDA); shares outstanding 0.13B to 0.12B, down 12.2% (pass). 2 of 4 tests passed; the framework scores that as 3.
Filings
Three kinds of event the company reported to the SEC in the last 5 years, from its filings on SEC EDGAR.
Loading...
These are events the company reported to the SEC. An auditor change or a late filing can have many causes; each date links to the filing, where the company explains it. Valerius does not score these.
Graham Formula:
IV = EPS x (8.5 + 2g) x (4.4 / Y)
EPS = $3.43, g = 1.7%, Y = 4.5
IV = $39.91
Current price $86.38 vs Graham value $39.91 — price is 116.4% above the model value.
DCF:
FCF/share = $3.915
Stage 1 growth = 3.4% for 5 years | terminal growth = 3.0% | discount rate = 10.0%
Y1: $4.048 → PV $3.680
Y2: $4.186 → PV $3.459
Y3: $4.328 → PV $3.252
Y4: $4.475 → PV $3.057
Y5: $4.628 → PV $2.873
Stage 1 PV sum = $16.32
Terminal value at end of Y5 = $68.09
PV of terminal value = $42.28
DCF value = $58.60
Current price $86.38 vs DCF value $58.60 — price is 47.4% above the model value.Data from yfinance summary figures and financial statements, and from the company’s 10-K filings via SEC EDGAR; computed at a price of $86.38. Every score is calculated from the figures by the framework’s fixed rules, and the explanation beside it is generated from the same figures: Graham value, DCF value, margin of safety, ROIC, profit margins, debt-to-equity, price-to-book, EPS trend, ROE trend, free cash flow, retained earnings and capital allocation. No AI is involved in this scorecard. The moat is shown as evidence, without a score. Read each score with the figures beside it. Intrinsic value calculations are model outputs based on stated assumptions, not predictions.
Recent headlines · third-party publishers · not investment advice
The 8 newest headlines whose title names the company, shown automatically and never chosen by Valerius. From third-party publishers via Yahoo Finance, linked to the source. Valerius doesn't write or endorse them. Not investment advice.